Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Lineage Cell Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 114
- +2 vs. Q2 2024
- Shares held
- 94.6M
- +9.69M (+11.4%) vs. Q2 2024
- Total value
- $85.6M
- +$966.7K (+1.1%) vs. Q2 2024
- New holders
- 9
- 29 more added
- Sold out
- 7
- 24 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 131 | $152.7M |
| Q1 2026 | 130 | $176.5M |
| Q4 2025 | 123 | $169.8M |
| Q3 2025 | 112 | $148.6M |
| Q2 2025 | 129 | $88.4M |
| Q1 2025 | 127 | $49.7M |
| Q4 2024 | 126 | $53.8M |
| Q3 2024 | 114 | $85.6M |
| Q2 2024 | 113 | $94.2M |
| Q1 2024 | 116 | $138.3M |
| Q4 2023 | 115 | $82.5M |
| Q3 2023 | 104 | $89.1M |
| Q2 2023 | 107 | $106.6M |
| Q1 2023 | 116 | $104.7M |
| Q4 2022 | 106 | $76.2M |
| Q3 2022 | 104 | $73.1M |
| Q2 2022 | 100 | $102.7M |
| Q1 2022 | 109 | $112.3M |
| Q4 2021 | 124 | $182.0M |
| Q3 2021 | 115 | $191.7M |
| Q2 2021 | 115 | $208.5M |
| Q1 2021 | 102 | $141.8M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Lineage Cell Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bridgeway Capital Management, LLC | 756,766 | $685.1K | 0.01% | +75,000+11.0% | Added |
| Morgan Stanley | 848,291 | $768.0K | 0.00% | +321,662+61.1% | Added |
| Northern Trust Corp | 1,274,573 | $1.15M | 0.00% | +83,255+7.0% | Added |
| DAFNA Capital Management LLC | 1,350,708 | $1.22M | 0.29% | 00.0% | Unchanged |
| Bank of America Corp | 1,372,422 | $1.24M | 0.00% | +11,497+0.8% | Added |
| MAI Capital Management | 1,674,679 | $1.52M | 0.01% | +35,907+2.2% | Added |
| State Street Corp | 2,608,352 | $2.36M | 0.00% | +45,483+1.8% | Added |
| Geode Capital Management, LLC | 3,679,280 | $3.33M | 0.00% | +83,274+2.3% | Added |
| Raffles Associates LP | 4,507,781 | $4.08M | 4.19% | +150,000+3.4% | Added |
| Logos Global Management LP | 5,000,000 | $4.53M | 0.51% | +300,000+6.4% | Added |
| Defender Capital, LLC. | 5,002,198 | $4.53M | 1.50% | +29,223+0.6% | Added |
| Vanguard Group Inc | 8,600,995 | $7.78M | 0.00% | +127,028+1.5% | Added |
| BlackRock, Inc. | 9,919,800 | $8.98M | 0.00% | +9,919,800 | New |
| Broadwood Capital Inc | 41,666,255 | $37.7M | 2.89% | 00.0% | Unchanged |
| Millennium Management LLC | 0 | $0 | 0.00% | −168,978−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −78,454−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −78,181−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −68,286−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −61,515−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −44,307−100.0% | Sold out |
| Crewe Advisors LLC | 0 | $0 | 0.00% | −1,016−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |